KO
KOD.US Kodiak Sciences Inc
- Market cap
- USD 7.27B
- P/E
- -
- P/B
- 579.00x
- ROE
- -2,015.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KOD.US undervalued?
Graham numberThe Graham number of Kodiak Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kodiak Sciences Inc fundamental analysis
No fundamental analysis for Kodiak Sciences Inc yet.
Kodiak Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-relat…
Full company profileKodiak Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kodiak Sciences Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -257K | -549K | -490K | -911K | -4.21M | -8.71M | -11.0M | -25.9M | -26.7M | - | - |
| Operating Income | -17.2M | -25.5M | -26.4M | -49.2M | -136M | -267M | -341M | -277M | -187M | -234M | -258M |
| EBITDA | -16.9M | -26.2M | -35.4M | -46.4M | -129M | -258M | -323M | -235M | -150M | -204M | -238M |
| Net Income | -17.1M | -27.9M | -41.4M | -47.4M | -133M | -267M | -334M | -260M | -176M | -230M | -253M |
| EPS | -2.30 | -1.05 | -1.16 | -1.25 | -2.91 | -5.16 | -6.39 | -4.97 | -3.35 | -4.32 | -4.02 |
| Balance Sheet | |||||||||||
| Total Assets | 12.1M | 3.24M | 92.2M | 359M | 1.07B | 904M | 667M | 479M | 336M | 352M | 209M |
| Total Liabilities | 53.2M | 72.0M | 5.36M | 13.5M | 207M | 241M | 230M | 214M | 185M | 194M | 197M |
| Shareholders' Equity | -41.1M | -68.7M | 86.8M | 345M | 861M | 663M | 436M | 266M | 150M | 157M | 12.6M |
| Cash & Short-term Investments | 9.62M | 1.40M | 88.3M | 336M | 969M | 732M | 479M | 286M | 168M | 210M | 88.7M |
| Total Debt | 185K | 12.4M | - | 1.94M | 77.4M | 180M | 188M | 182M | 70.3M | 159M | 147M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.0M | -17.7M | -29.0M | -39.1M | -83.4M | -182M | -206M | -154M | -117M | -136M | -173M |
| Capital Expenditure | 771K | 209K | 581K | 437K | 7.00M | 63.3M | 47.4M | 41.4M | 400K | 506K | 4.37M |
| Free Cash Flow | -16.8M | -17.9M | -29.6M | -39.6M | -90.4M | -246M | -254M | -196M | -118M | -137M | -178M |
| Ratios | |||||||||||
| ROE | - | - | -47.7% | -13.7% | -15.5% | -40.3% | -76.5% | -98.0% | -117.2% | -146.1% | -2,015.3% |
| ROA | -141.4% | -861.2% | -45.0% | -13.2% | -12.5% | -29.5% | -50.1% | -54.3% | -52.5% | -65.4% | -121.0% |
| Debt to Equity | - | - | - | 0.01x | 0.09x | 0.27x | 0.43x | 0.68x | 0.47x | 1.01x | 11.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kodiak Sciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 7.91M | 0.15 | - |
| 2021 | USD 10.0M | 0.19 | - |
| 2020 | USD 6.25M | 0.14 | - |
| 2019 | USD 2.29M | 0.06 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Feb 23, 2022.
Who owns Kodiak Sciences Inc
- Insiders 5.20%
- Institutions 94.80%
- Public & others 0.00%
- Shares outstanding 65.4M
- Free float 38.1M
Top funds holding KOD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 1.38M | 2.14% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.29M | 2.01% | +0.02% | Sep 2026 |
| iShares Russell 2000 ETF | 1.00M | 1.56% | 0.00% | Oct 2026 |
| T. Rowe Price Health Sciences | 841K | 1.31% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 769K | 1.20% | +1.06% | Sep 2026 |
| Artisan International Small-Mid Investor | 596K | 0.93% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 558K | 0.87% | -11.03% | Sep 2026 |
| iShares Biotechnology ETF | 452K | 0.70% | -0.44% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 433K | 0.67% | -17.00% | Sep 2026 |
| Fidelity Small Cap Index | 431K | 0.67% | +0.14% | Aug 2026 |
| T. Rowe Price Instl Small-Cap Stock | 428K | 0.67% | +2.71% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 370K | 0.57% | -0.38% | Oct 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 308K | 0.48% | +5.07% | Jun 2026 |
| Vanguard Russell 2000 ETF | 229K | 0.36% | +0.98% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 210K | 0.33% | +0.23% | Oct 2026 |
| Vanguard Explorer Inv | 204K | 0.32% | -16.95% | Sep 2026 |
| Fidelity Extended Market Index | 180K | 0.28% | -9.76% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 158K | 0.25% | +0.27% | Oct 2026 |
| Bruce | 130K | 0.20% | -10.34% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 121K | 0.19% | 0.00% | Sep 2026 |
Top institutions holding KOD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 19.9M | 30.98% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.14M | 6.43% | +5.08% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.25M | 5.05% | +59.30% | Jun 2026 |
| State Street Corp | 2.42M | 3.76% | +7.49% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.32M | 3.60% | +37.12% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.80M | 2.81% | +5.10% | Jun 2026 |
| BRAIDWELL LP | 1.79M | 2.78% | -1.72% | Jun 2026 |
| Jupiter Topco LLC | 1.53M | 2.37% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.49M | 2.31% | 0.00% | Jun 2026 |
| Boxer Capital Management, LLC | 1.48M | 2.30% | +8.57% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.48M | 2.30% | +76.48% | Jun 2026 |
| TCG Crossover Management, LLC | 1.45M | 2.25% | 0.00% | Jun 2026 |
| ICONIQ Capital, LLC | 1.27M | 1.97% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.06M | 1.65% | +6.25% | Jun 2026 |
| Ikarian Capital, LLC | 1.06M | 1.65% | -16.28% | Jun 2026 |
| Artisan Partners Limited Partnership | 968K | 1.51% | +40.23% | Jun 2026 |
| Wellington Management Company LLP | 794K | 1.23% | +81.88% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 546K | 0.85% | -44.93% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 533K | 0.83% | +45.96% | Jun 2026 |
| Squadron Capital Management LLC | 500K | 0.78% | +31.58% | Jun 2026 |
Kodiak Sciences Inc company profile
- Company name
- Kodiak Sciences Inc
- Ticker
- KOD.US
- Exchange
- USA Stocks
- Listed since
- Oct 4, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 144
- Fiscal year end
- December
- Address
- 1250 Page Mill Road, Palo Alto, CA, United States, 94304
- Phone
- 650 281 0850
- Website
- kodiak.com
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Kodiak Sciences Inc management
9- Dr. Victor Perlroth M.D.Co-Founder, Chairman, CEO & President · born 1974
- Mr. John A. Borgeson CPA, M.B.A.Executive VP, CFO & Secretary · born 1963
- Mr. Wayne To M.Phil.Chief Technology Officer
- Dr. Dolly S. Chang M.D., M.P.H., Ph.D.Chief Scientific Officer
- Dr. Hong Liang Ph.D.Senior Vice President of Development · born 1972
- Dr. Stephen Raillard Ph.D.Senior Vice President of Chemical Development & Manufacturing
- Ms. Almas Qudrat M.Sc.Chief Quality Officer
- Dr. J. Pablo Velazquez-Martin M.D.Chief Medical Officer
- Dr. Laurent Ducay Ph.D.Senior VP of Biologics Development & Manufacturing